Summary CA242 has been proved to be useful in the diagnosis of pancreatic cancer. The aim of the present study was to clarify the mechanisms contributing to the high specificity of CA242 as compared with CA19-9 resulting from scarce serum elevation of this antigen in patients with chronic pancreatitis by correlating serum levels and endoscopic retrograde choledocho-pancreatography (ERCP) findings and by immunohistochemical analysis. Serum CA19-9 levels were significantly elevated in patients with calcification and with main pancreatic duct (MPD) stenosis or obstruction. On the other hand, serum CA242 levels showed no significant elevation in patients with such factors. Even though such pathological conditions were considered to lead to the stagnation of pancreatic juice, serum CA242 levels seemed to be less affected than serum CA19-9 levels. Immunohistochemical studies of chronic pancreatitis tissues revealed that CA242 was expressed less frequently and less intensely than CA19-9, and the difference in expression was more prominent in the centroacinar cells and terminal ductules. From the results of the present study, it is conceivable that CA242 is less influenced by the stagnation of the pancreatic juice than CA19-9 because of the low levels of expression in ductal systems, which results in the release of this antigen into the circulation in lower amounts than that of CA19-9.
In a previous study, we reported that the new tumour marker CA242 showed sensitivity similar to that of CAl9-9 for overall cases and early cases (stage I tumour) of pancreatic cancer, and was only slightly and infrequently elevated in the sera of patients with benign diseases, as also reported by others Kawa et al., 1994a; Johansson et al., 1991a; Nilsson et al., 1992; Pasanen et al., 1992; Banfi et al., 1993; Rothlin et al., 1993; Haglund et al., 1994) . These findings suggest the usefulness of this marker for screening pancreatic cancer patients on their first hospital visit. Although the epitope recognised by the monoclonal antibody (MAb) C242 used in this assay system has not yet been fully elucidated, C242 showed unique characteristics in that it has no reactivity to sialosyl-fucosyl-lactotetraose (sialyl Lewisa) or sialosyl-lactotetraose (sialyl Lewisc) (Johanson et al., 1991b; Kuusela et al., 1991) , whereas MAbs for established tumour markers useful for diagnosis of pancreatic cancer were confirmed to have reactivities to either or both structures; NS19-9 for sialyl Lewisa, DUPAN-2 MAb for sialyl Lewisc, C50 and Span-1 MAb mainly for sialyl Lewisa and in part for sialyl Lewisc (Magnani et al., 1982; Nilsson et al., 1985; Kawa et al., 1994b) .
The differentiation of pancreatic cancer from chronic pancreatitis is sometimes difficult clinically at the time of admission, and false positivity in tumour markers leads to further imaging tests, which is wasteful of these facilities. As reported previously, the specificity of CA242 (86%) was higher than that of CA19-9 (76%) calculated from the results of chronic pancreatitis, using cut-off values of 30 and 37 U ml-1 (CA242 and CA19-9, respectively) both of which provided optimal discrimination between pancreatic cancer and benign diseases (Del Villano et al., 1983; Kawa et al., 1994a) and favourable results in detecting Stage I pancreatic cancer (Kawa et al., 1994a) . Using cut-off values of 35 and 80 U ml-' (CA242 and CA19-9 respectively) corresponding to the 90% of specificity level for chronic pancreatitis, elevated CA242 and CA19-9 levels were seen in 78% and 72% of the patients with pancreatic cancer respectively (Kawa et al., 1994a) . These results indicate that this marker will provide a new tool for the discrimination of both conditions. However, it is not certain why CA242 has an advantage over CA19-9 in its higher specificity. Tissue expression of CA242 was reported to be similar to that of CA19-9, in which both antigens were expressed mainly in the apical border of ductal cells and luminal content, but also to some extent intracellularly (Haglund et al., 1989) , indicating that CA242 was secreted into the pancreatic juice. As reported for CA19-9, which is expressed at high levels in epithelial cells of the bile duct system (Arends et al., 1983; Kobayashi et al., 1991) , it could be possible from its similar tissue localisation that CA242 is also secreted into the bile juice. Accordingly, serum elevation of both markers in patients with chronic pancreatitis may be caused by one of the following mechanisms: (1) stagnation of the pancreatic juice; (2) necrosis of pancreatic tissue; and (3) cholestasis. These pathological conditions can be to some extent assessed by endoscopic retrograde choledocho-pancreatography (ERCP) and computed tomography (CT) findings. Stagnation of the pancreatic juice can be caused by the stenosis or obstruction of the main pancreatic duct (MPD) and pancreatic stones and necrosis of the pancreatic tissue leads to the formation of pseudocysts. Extrahepatic cholestasis is related to stenosis of the intrapancreatic bile duct. The aim of the present study was to clarify the mechanisms operating in the scarce serum elevation of CA242 as compared with CA19-9 in patients with chronic pancreatitis by correlating serum levels with ERCP and CT findings and by immunohistochemical analysis. 
Materials and methods

Results
Effects of complications
Of 70 cases, 14 were complicated with overt diabetes mellitus. No significant differences in serum levels for each marker were found between patients with and without diabetes mellitus (data not shown). With regard to other complications, we found three patients with benign liver diseases and no patients with renal failure. Because of the small number of patients, these complications had no effects on the serum elevation of each marker in the patient groups enrolled in this study.
Correlation between serum levels and each ERCP finding For CA19-9, the serum level was likely to be affected by pathological conditions related to stagnation of pancreatic juice, and a significant difference was found between patients with and without MPD stenosis or obstruction and with and without calcification by Mann-Whitney U-test (Figure 2) . The presence of pseudocysts and CBD stenosis seemed to exert no effect on the serum level of CA19-9. For CA242, no significant differences in serum levels were found between patients with and without these factors. Analysis with Welch t-test showed almost the same results, the only significant difference of serum CA19-9 levels being found between patients with and without MPD stenosis or obstruction (Table I) .
Immunostaining of each marker
The frequency and intensity of the expression of each marker in 12 chronic pancreatitis tissues are summarised in Figure  3a . CA242 was expressed less at various levels of the duct systems as compared with CA19-9 (sialyl Lewisa). The difference in the expression of these markers was marked, especially in the centroacinar cells and the terminal ductules in some cases (Figure 4) . However, CA242 was highly expressed in hyperplasia and the large ducts of tissues of some patients with ERCP findings related to stagnation of pancreatic juice. The localisation of each antigen in small and large ducts was also compared to examine whether the elevation of serum level was influenced by disturbed antigen polarity (Figure 3b ). The disturbed antigen polarity, i.e. cytoplasmic staining, was infrequently seen in the expression of both CA242 and CA19-9.
CA242 Discussion
In chronic pancreatitis, the mechanisms operating in the false elevation of serum tumour marker are classified into two categories: the structural changes occurring in the pancreas and complications that are not directly related to these structural changes. Benign liver diseases (chronic hepatitis and liver cirrhosis) and diabetes mellitus are major complications leading to the false elevation of conventional tumour markers in this disease. However, neither condition exerted any effect on serum elevation of the tumour markers in the patient groups enrolled in this study. Accordingly our attention was focused on the structural changes occurring in the pancreas that were considered to be associated with the false elevation of serum levels.
The elevation of serum CA242 levels was not affected by the presence of calcification, MPD stenosis or obstruction, pseudocysts or stenosis of the intrapancreatic bile duct, indicating that these factors had no effects on the serum elevation of this marker. On the other hand, serum CA19-9 levels were significantly elevated in patients with calcification and with MPD stenosis or obstruction. While such pathological conditions were considered to lead to the stagnation of pancreatic juice, serum CA242 levels seemed to be less affected by these conditions than serum CA19-9 levels. Immunohistochemical studies revealed that CA242 was expressed in the cells of various ductal systems less frequently and less intensely compared with CA19-9, which was more prominent in the centroacinar cells and terminal ductules. These findings were in disagreement with those of a previous report (Haglund et al., 1989) , in which the expression of CA242 was similar to that of CA19-9. From the findings of the present study, it is conceivable that the small amounts of CA242 in ductal cells were scarcely affected by stagnation of pancreatic juice, resulting in the release of this antigen into the circulation in smaller amounts than CA19-9, which was found to be extensively expressed.
We found no previous reports concerning the correlation between serum elevation of tumour marker and the ERP findings in patients with chronic pancreatitis. CA19-9 levels of pancreatic juice were reported to be higher in patients with calcifications (Tatsuta et al., 1985; Malesci et al., 1987) , indicating that antigens could be concentrated in this condition. Although these findings could not explain the mechanism of serum elevation, they may support the thesis that pathological conditions related to stagnation of pancreatic juice play a significant role. The mechanisms concerning the false serum elevation of tumour markers in chronic pancreatitis have been analysed by means of immunohistochemical study. Satomura et al. (1991) reported that disturbed antigen polarity plays a significant role in the elevation of serum CA19-9 levels. In chronic pancreatitis tissues, cytoplasmic staining was observed in addition to apical staining, whereas only apical staining was seen in normal pancreatic tissues. The correlation between the disturbed antigen polarity and serum level was reported to be more prominent in pancreatic cancer tissues (Satomura et al., 1991) . However, a different study demonstrated no such relationship in colorectal cancer tissues for CEA and CAl9-9 (Tabuchi et al., 1988) . In the present study, both antigens were mainly expressed in the apical surface of duct cells, indicating that the disturbed antigen polarity may play a small part, if any, in the false serum elevation of these antigens.
In conclusion, the elevation of serum CA242 levels in patients with chronic pancreatitis is considered to be less influenced by the pathological conditions related to stagnation of pancreatic juice as compared with CAI 9-9 because of its low level of expression in ductal systems. These results further support the idea that CA242 is different from the established tumour marker sialyl 
